| Literature DB >> 30687124 |
Elise Vogel1, Dulce Santos1, Lina Mingels1, Thomas-Wolf Verdonckt1, Jozef Vanden Broeck1.
Abstract
Insects constitute the largest and most diverse group of animals on Earth with an equally diverse virome. The main antiviral immune system of these animals is the post-transcriptional gene-silencing mechanism known as RNA(i) interference. Furthermore, this process can be artificially triggered via delivery of gene-specific double-stranded RNA molecules, leading to specific endogenous gene silencing. This is called RNAi technology and has important applications in several fields. In this paper, we review RNAi mechanisms in insects as well as the potential of RNAi technology to contribute to species-specific insecticidal strategies. Regarding this aspect, we cover the range of strategies considered and investigated so far, as well as their limitations and the most promising approaches to overcome them. Additionally, we discuss patterns of viral infection, specifically persistent and acute insect viral infections. In the latter case, we focus on infections affecting economically relevant species. Within this scope, we review the use of insect-specific viruses as bio-insecticides. Last, we discuss RNAi-based strategies to protect beneficial insects from harmful viral infections and their potential practical application. As a whole, this manuscript stresses the impact of insect viruses and RNAi technology in human life, highlighting clear lines of investigation within an exciting and promising field of research.Entities:
Keywords: RNA interference; antiviral immunity; delivery systems; environmental RNAi; insecticides; insects; systemic RNAi; viruses
Year: 2019 PMID: 30687124 PMCID: PMC6336832 DOI: 10.3389/fphys.2018.01912
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
FIGURE 1Simplified model of environmental, cell autonomous and systemic (antiviral) RNAi in insects. The siRNA pathway is triggered by dsRNA molecules. These duplexes naturally occur inside the cell during viral replication or can be artificially delivered. In the latter, cellular uptake of dsRNA, i.e., environmental RNAi, occurs via scavenger receptor-mediated endocytosis. Once inside the cell, i.e., cell autonomous RNAi, the dsRNA molecules are recognized in the cytoplasm and processed into siRNAs by Dcr2. Cleavage of viral RNA targets or endogenous transcripts is then further exerted by an Ago2-containing RISC, which encompasses the siRNA guide strand. Regarding antiviral RNAi in Drosophila, viral infection increases the formation of nanotube-like structures, through which short-distance transport of dsRNA and RISC components can occur. In addition, hemocyte-derived exosome-like vesicles systemically spread an antiviral RNAi signal (vsRNAs) in the hemolymph. This spread of the RNAi signal to cells in which the RNAi response had not been initiated before is named systemic RNAi. dsRNA, double stranded RNA. Dcr2, Dicer2. siRNA, small interfering RNA. RISC, RNA-induced silencing complex. Ago2, Argonaute2. vsRNA, viral small RNAs.
Overview of delivery systems used for the successful delivery of dsRNA in several economically important insect orders.
| Insect order | Category | Delivery system | Species | Target gene∗ | Reference |
|---|---|---|---|---|---|
| Lepidoptera | Micro-organism | Bacteria | |||
| Viral | BmNPV | ||||
| AcMNPV | |||||
| Sindbis Virus | |||||
| Nanoparticle | FNP | ||||
| Guanylated polymers | |||||
| Coleoptera | Micro-organism | Bacteria | |||
| Proteinaceous | PTD-DRBD | ||||
| Hemiptera | Micro-organism | Bacterial symbiont – | |||
| Bacterial symbiont – | |||||
| Diptera | Micro-organism | Yeast symbiont – | |||
| Nanoparticles | |||||
| Liposomes | Lipofectamine 2000, Cellfectin, Transfectin, BMRIE-C | ||||
| Lipofectamine 2000 | |||||
| Effectene | |||||
FIGURE 2Patterns of viral infection. Acute infections are represented by a high increase in viral levels and are limited in time either by the death of the host or by the clearance of the virus by the host immune system. Persistent infections consist in constant, but relatively low, viral levels and can manifest themselves for long periods of time. Latent infections consist in the presence of the viral genome in the host cell without actual production of viral particles. During this latency, viruses maintain the potential to resume viral replication and start producing viral particles (reactivation). Chronic infections are generally defined as the outcome of an acute infection in which neither host mortality nor virus clearance occur, meaning a persistent or latent outcome derived from an acute infection. Slow infections are characterized by a slow, but not constant, increasing in viral levels overtime.
Overview of viruses with a significant impact on beneficial insects and on economically relevant shrimps.
| Beneficial arthropods | Infecting virus | Genome - Taxonomy (Genus) | Host stage | Symptoms acute stage | Reference |
|---|---|---|---|---|---|
| Sacbrood Virus | +ssRNA – Iflavirus | Pupae/Adults | Failure to pupate, death | ||
| Varroa destructor virus-1 | +ssRNA – Iflavirus | Pupae/Adults | Deformed wings, shortened lifespan, Colony collapse | ||
| Chronic Bee Paralysis Virus | +ssRNA – Noda/Tombus-virus | Adults | Paralysis, death | ||
| Black Queen Cell Virus | +ssRNA – Cripavirus | Pre-/Pupae | Decomposed and black pre-/pupae | ||
| Kashmir Bee Virus | +ssRNA – Dicistrovirus | Adults/pupae | Reduced fecundity, death | ||
| Israeli Acute Paralysis Virus | +ssRNA – Dicistrovirus | Adults | Reduced fecundity, paralysis, darkening, hair loss, death | ||
| Acute Bee Paralysis Virus | +ssRNA – Dicistrovirus | Adults | Paralysis, darkening, hair loss, death | ||
| Deformed Wing Virus | +ssRNA – Iflavirus | Pupae/Adults | Deformed wings, shortened lifespan, Colony collapse | ||
| Slow Bee Paralysis Virus | +ssRNA – Iflavirus | Pupae/Adults | Paralysis of anterior legs, death | ||
| dsDNA – Alphabaculovirus | Larvae/Pupae/Adults | Molting failure, hyperactivity, translucent skin, white hemolymph, death | |||
| dsRNA – Cypovirus | Larvae/Pupae/Adults | Delayed larval growth, failure to pupate | |||
| Infectious Flacherie Virus | +ssRNA – Iflavirus | Larvae | Flaccidity, retarded growth, death | ||
| ssDNA – Iteravirus | Larvae | Flaccidity, retarded growth, death | |||
| Taura Syndrome Virus | +ssRNA – Cripavirus | All stages | Lethargy, epithelial necrosis of entire body, death | ||
| Infectious Hypodermal and Hematopoietic Necrosis Virus | ssDNA – Brevidensovirus | Juvenile, Adults | Cuticular deformities, impaired growth, death | ||
| Yellow Head Virus | +ssRNA – Okavirus | All stages | Yellow discoloration, systemic necrosis, death | ||
| White Spot Syndrome Virus | dsDNA – Whispovirus | Juveniles, Adults | White spots, red/yellow discoloration, death | ||
| Infectious Myonecrosis Virus | dsRNA – Unclassified | Juveniles, Subadults | White spots in, and necrosis of, skeletal muscles, death |
Summary of the investigated strategies to obtain improved antiviral defense in insects and in economically relevant crustacean species.
| Species | Virus | Strategy | Outcome | Reference | |
|---|---|---|---|---|---|
| IAPV | Oral delivery of virus-specific dsRNA | Lower mortality; lower viral transcript levels | |||
| IAPV | Oral delivery of Remebee-I (a IAPV-specific dsRNA product) | Florida colony: higher bee population per hive; higher adult forager activity; higher hive total weight gain (honey); Pennsylvania colony: higher hive total weight gain (honey); lower Nosema levels. | |||
| DWV | Oral delivery of virus-specific dsRNA | Lower proportion of adult bees with deformed wings; lower viral transcript levels; adult survival was not affected | |||
| SINV-GFP | Injection of virus-specific and unspecific dsRNA | Lower viral abundance | |||
| SINV-GFP | Injection of virus-specific and unspecific dsRNA | Lower viral abundance | |||
| CSBV | Oral delivery of virus-specific dsRNA | Lower larvae mortality; lower viral transcript levels | |||
| CSBV | Oral delivery of virus-specific dsRNA | Lower larvae mortality; lower viral transcript levels | |||
| IAPV | Oral delivery of virus-specific and unspecific dsRNA | Lower viral transcript levels in the head | |||
| AcNPV-GFP | Injection of virus-specific dsRNA | Lower mortality | |||
| AcNPV-GFP | Transfection with virus-specific dsRNA | Reduced fluorescence; lower viral protein levels; lower viral transcript levels; lower amount of viral particles; reduced cell morphological changes | |||
| BmNPV | Expression (transient transfection) of virus-specific dsRNA | Lower virus titer in the cell culture medium | |||
| BmNPV | Expression (constitutive transfection) of virus-specific dsRNA | Lower virus titer in the cell culture medium; lower viral transcript levels in the cells | |||
| BmNPV | Transgenic animals expressing virus-specific dsRNA | Reduced levels of viral DNA in the hemolymph | |||
| AcNPV | Expression (constitutive transfection) of virus-specific dsRNA | Lower virus titer in the cell culture medium; reduced OBs in the cells | |||
| BmNPV and GFP-BmNPV | Transgenic animals expressing virus-specific dsRNA | Lower mortality; reduced levels of OBs in the hemolymph; reduced fluorescence; reduced viral protein levels; lower viral transcript levels | |||
| BmNPV | Transgenic animals expressing single or multiple virus-specific dsRNAs (targeting different genes) | Lower mortality rates; lower levels of OBs in the hemolymph; lower viral DNA levels; reduced viral protein levels | |||
| BmCPV | Transgenic animals expressing single or multiple virus-specific dsRNAs (targeting different genes) | Lower mortality rates; lower viral transcript levels | |||
| CrPV | Expression (transient transfection) of BmDicer2 and BmArgonaute2 | Reduced cell mortality | |||
| TSV and WSSV | Injection of unspecific dsRNA | Lower mortality; lower accumulation of viral particles; lower levels of tissue damage. | |||
| WSSV | Injection of virus-specific dsRNA | Lower mortality | |||
| WSSV | Injection of unspecific dsRNA of multiple sizes (50–200 bp) | Lower mortality | |||
| WSSV | Injection of virus-specific and unspecific dsRNA | Lower mortality | |||
| YHV | Transfection of virus-specific and unspecific dsRNA | Reduced cytopathic effects; lower viral transcript levels in the cell medium; lower viral protein levels | |||
| YHV | Injection of virus-specific dsRNA | Lower viral transcript levels; reduced mortality | |||
| YHV | Injection of unspecific dsRNA | Lower mortality | |||
| DNV | Injection of virus-specific dsRNA | Lower viral DNA levels |
FIGURE 3Impact of RNAi technology and of insect viral infections in human life. The RNAi technology, represented by the dashed green line, promises to exert protection against pest insects, such as the ones threatening crop production and the ones constituting vectors for viral diseases. This technology also holds potential to protect beneficial insects from harmful viral infections. In addition, insect viruses constitute important bio-insecticides.